LitCovid-sentences  

PMC:7309518 / 0-1792 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T1 0-24 Sentence denotes Guillain-Barré syndrome:
T2 25-94 Sentence denotes The first documented COVID-19–triggered autoimmune neurologic disease
T3 95-135 Sentence denotes More to come with myositis in the offing
T4 137-145 Sentence denotes Abstract
T5 146-155 Sentence denotes Objective
T6 156-380 Sentence denotes To present the COVID-19–associated GBS, the prototypic viral-triggered autoimmune disease, in the context of other emerging COVID-19–triggered autoimmunities, and discuss potential concerns with ongoing neuroimmunotherapies.
T7 382-389 Sentence denotes Methods
T8 390-572 Sentence denotes Eleven GBS cases in four key COVID-19 hotspots are discussed regarding presenting symptoms, response to therapies and cross-reactivity of COVID spike proteins with nerve glycolipids.
T9 573-762 Sentence denotes Emerging cases of COVID-19–triggered autoimmune necrotizing myositis (NAM) and encephalopathies are also reviewed in the context of viral invasion, autoimmunity and ongoing immunotherapies.
T10 764-771 Sentence denotes Results
T11 772-996 Sentence denotes Collective data indicate that in this pandemic any patient presenting with an acute paralytic disease-like GBS, encephalomyelitis or myositis-even without systemic symptoms, may represent the first manifestation of COVID-19.
T12 997-1113 Sentence denotes Anosmia, ageusia, other cranial neuropathies and lymphocytopenia are red flags enhancing early diagnostic suspicion.
T13 1114-1470 Sentence denotes In Miller-Fisher Syndrome, ganglioside antibodies against GD1b, instead of QG1b, were found; because the COVID-19 spike protein also binds to sialic acid-containing glycoproteins for cell-entry and anti-GD1b antibodies typically cause ataxic neuropathy, cross-reactivity between COVID-19–bearing gangliosides and peripheral nerve glycolipids was addressed.
T14 1471-1695 Sentence denotes Elevated Creatine Kinase (>10,000) is reported in 10% of COVID-19–infected patients; two such patients presented with painful muscle weakness responding to IVIg indicating that COVID-19–triggered NAM is an overlooked entity.